Uterine Sarcoma: Causes, Symptoms, Diagnosis and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Uterine sarcomas are rare malignant tumors arising from the mesenchymal components of the uterus, accounting for approximately 3-9% of all uterine cancers with an annual US incidence of approximately 1,500-2,000 cases. The major histological subtypes are uterine leiomyosarcoma (LMS, approximately 60%), low-grade endometrial stromal sarcoma (LG-ESS, approximately 15%), high-grade endometrial stromal sarcoma (HG-ESS, approximately 5%), and undifferentiated uterine sarcoma (UUS, approximately 10%). Carcinosarcoma (malignant mixed Mullerian tumor) is now classified and treated as high-grade endometrial carcinoma rather than a true sarcoma. Each subtype has distinct molecular drivers, clinical behavior, and treatment approach, making subtype-specific pathological characterization essential. Uterine sarcomas are typically diagnosed at a more advanced stage than endometrial carcinomas, and overall prognosis is significantly worse. Uterine Sarcoma: Causes, Symptoms, Diagnosis and Treatment is a medical condition that affects patients across various age groups and demographics. It requires proper medical attention and management. This page provides evidence-based information about Uterine Sarcoma: Causes, Symptoms, Diagnosis and Treatment to help patients understand the condition, its causes, symptoms, and available treatment options.

Uterine LMS is predominantly sporadic. Prior pelvic radiation therapy (latency 5-20 years) is an established risk factor for secondary uterine sarcoma. Tamoxifen use — which exerts estrogenic effects on the uterus — is associated with increased uterine sarcoma risk with long-term use, particularly carcinosarcoma. Hereditary leiomatosis and renal cell carcinoma syndrome (HLRCC, FH gene mutation) predisposes to uterine smooth muscle tumors including LMS. Low-grade ESS is characterized by JAZF1-SUZ12 gene fusion (t(7;17)) in the majority of cases. High-grade ESS harbors YWHAE-NUTM2 fusions from t(10;17). Undifferentiated uterine sarcoma lacks specific genetic markers. Black women have a 2-fold higher incidence of uterine LMS compared to White women, possibly related to hormonal factors and prior radiation exposure differences.

Abnormal uterine bleeding — including postmenopausal bleeding or heavy irregular menstrual bleeding in premenopausal women — is the most common presenting symptom, occurring in 50-80% of patients. Pelvic pain or pressure and sensation of a pelvic mass are frequent, particularly with larger tumors. A rapidly enlarging uterine mass (especially in a postmenopausal woman) raises concern for LMS, though this is not a reliable discriminator from benign fibroids. Advanced disease may present with abdominal distension from ascites or peritoneal disease, lower extremity edema from lymphatic obstruction, or urinary and bowel symptoms from local compression. Constitutional symptoms including unintentional weight loss, fatigue, and night sweats suggest metastatic disease. Many cases are diagnosed incidentally at pathological examination of hysterectomy or myomectomy specimens.

Preoperative diagnosis of uterine sarcoma is challenging, as imaging cannot reliably distinguish LMS from large benign fibroids. MRI pelvis with diffusion-weighted imaging provides the best soft tissue characterization — irregular margins, heterogeneous signal, central necrosis, and high DWI signal suggest sarcoma. Endometrial biopsy or curettage has low sensitivity for LMS (which arises in myometrium) but may diagnose ESS. PET-CT or CT chest/abdomen/pelvis is essential for staging metastatic disease. Diagnosis is usually confirmed on final pathology after hysterectomy. FIGO 2023 staging applies to all uterine sarcomas. Molecular profiling is mandatory: JAZF1/SUZ12 FISH for ESS classification, ER/PR receptor status (ESS), CDK4 amplification, and NGS panel for LMS and UUS to identify targetable alterations. Morcellation is absolutely contraindicated when sarcoma is suspected as it disseminates tumor cells and dramatically worsens prognosis.

Total abdominal hysterectomy with bilateral salpingo-oophorectomy (TAH-BSO) is the cornerstone of treatment for all stages of uterine sarcoma. Systematic lymphadenectomy has not proven to improve survival in LMS but is performed in ESS for staging. Bilateral oophorectomy is strongly recommended in LMS; in premenopausal women with LG-ESS, ovarian preservation may be considered with caveats. Adjuvant radiotherapy reduces local pelvic recurrence in high-grade sarcoma but does not improve overall survival. Adjuvant chemotherapy with gemcitabine plus docetaxel is commonly used for LMS, though benefit remains uncertain from randomized data. Metastatic LMS: gemcitabine-docetaxel is standard first-line; doxorubicin ± ifosfamide as alternative; trabectedin, pazopanib, and anlotinib for subsequent lines. Low-grade ESS: aromatase inhibitors (letrozole, anastrozole) or medroxyprogesterone acetate are highly effective, even in metastatic disease, given the hormone receptor-positive biology.

Uterine sarcoma prognosis is strongly determined by histological subtype and stage, with significant variation across the major subtypes. Uterine leiomyosarcoma (LMS) — the most common uterine sarcoma — carries a poor overall prognosis. Stage I LMS (confined to the uterus) has a 5-year overall survival of approximately 50–65% after hysterectomy alone; stages III and IV carry a 5-year survival below 25% and 10% respectively. Distant metastases are present in 15–30% of patients at diagnosis, most commonly in the lungs. High-grade endometrial stromal sarcoma (HG-ESS) and undifferentiated uterine sarcoma (UUS) have similarly aggressive behavior, with stage I 5-year survival of 50–60% and stage III–IV below 30–40%. Adjuvant gemcitabine-docetaxel chemotherapy is used for high-risk LMS, though survival benefit over observation for stage I–II resected LMS is modest and not definitively established by randomized trials. Low-grade endometrial stromal sarcoma (LG-ESS) has a markedly more favorable prognosis — stage I 5-year survival exceeds 85–90%, even though late recurrences (>5–10 years) are characteristic due to the estrogen-driven, indolent biology; hormone receptor positivity allows treatment with aromatase inhibitors with good long-term disease control in recurrent cases. Uterine morcellation of an undiagnosed sarcoma — previously common in laparoscopic myomectomy — dramatically worsens prognosis by disseminating tumor throughout the peritoneal cavity, upgrading the apparent stage and reducing survival by approximately 50% in LMS studies; this was the basis for FDA's strong warning against power morcellation. Trabectedin and pazopanib are approved second-line options for advanced uterine LMS.

No specific lifestyle interventions are proven to prevent uterine sarcoma. Avoidance of unnecessary pelvic radiation and appropriate monitoring of patients who received prior pelvic radiotherapy reduces secondary sarcoma risk. Women taking long-term tamoxifen (>5 years) for breast cancer should undergo annual pelvic ultrasound surveillance and report any abnormal uterine bleeding promptly, as tamoxifen is associated with uterine sarcoma risk. Women with HLRCC syndrome (fumarate hydratase gene mutation) require regular gynecological surveillance. Uterine morcellation should not be performed without thorough preoperative assessment to exclude sarcoma, as inadvertent morcellation of undiagnosed LMS significantly worsens prognosis by disseminating tumor cells. All postmenopausal bleeding requires investigation regardless of prior uterine pathology.

Any postmenopausal vaginal bleeding requires immediate gynaecological evaluation — this symptom is a hallmark of uterine pathology and must not be dismissed. Premenopausal women with heavy or irregular uterine bleeding that has changed in character, or that does not respond to hormonal management, should be assessed. A rapidly enlarging pelvic or uterine mass — particularly in a postmenopausal woman — requires urgent imaging and specialist review. Pelvic pain that is constant, progressive, or associated with a pelvic mass warrants evaluation. Symptoms of advanced disease — unexplained weight loss, abdominal swelling, or lower extremity swelling — should prompt urgent assessment. Women with known HLRCC syndrome or a history of pelvic radiation therapy should maintain regular gynaecological surveillance even without symptoms, as early detection of sarcoma significantly improves surgical resectability and survival.